Latest Breaking News On - Lingying wu - Page 1 : comparemela.com

Zejula Maintenance Decreases Progression, Death Risk in Ovarian Cancer

Frontline Zejula maintenance therapy decreased the risk of disease progression or death in patients with newly diagnosed ovarian cancer.

Rafaelg amadoLingying wuNational clinical research centerGlobal oncology researchZai labDepartment of gynecologic oncologyIncreased usePatients with ovarianGynecologic oncologyOvarian cancer

Zai Lab Limited (ZLAB) and Seagen (SGEN) Enter Collaboration and License Agreement for TIVDAK

Zai Lab Limited (ZLAB) and Seagen (SGEN) Enter Collaboration and License Agreement for TIVDAK
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongWilliam liangLingying wuMediadanielle halstrom xiaoyu chenNatasha herndayDavid caouetteAlina zhangGenmab collaborationDoug maffeiGreater china at zai labZai labEuropean unionZai lab forwardCompany quarterly report on formNational cancer center clinical research

Zai Lab Presents Positive Results from Phase 3 PRIME Study

PRIME study demonstrates that niraparib treatment had a statistically significant and clinically meaningful improvement in progression-free survival in the.

United kingdomHong kongAlan sandlerRon aldridgeAlina zhangLingying wuDanielle halstrom xiaoyu chenZai labZai lab limitedZai laboratoryChina national medical products administrationNational healthcare security administrationZai lab forwardSociety of gynecologic oncologyNational cancer center clinical researchUnion medical college

Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United kingdomHong kongAlan sandlerRon aldridgeAlina zhangLingying wuDanielle halstrom xiaoyu chenZai labZai lab limitedZai laboratoryChina national medical products administrationNational healthcare security administrationZai lab forwardSociety of gynecologic oncologyNational cancer center clinical researchUnion medical college

2021 CSCO | Henlius wird vier mündliche Präsentationen von zwei bevorstehenden kommerziellen Produkten vorstellen: Neuartiges Anti-PD-1-mAb Serplulimab und Bevacizumab-Biosimilar

2021 CSCO | Henlius wird vier mündliche Präsentationen von zwei bevorstehenden kommerziellen Produkten vorstellen: Neuartiges Anti-PD-1-mAb Serplulimab und Bevacizumab-Biosimilar
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesShukui qinJin liLingying wuChinese academyUnion as wellChinese societyNew drugSerplulimab forNational medicalNanjing bayi hospitalShanghai east hospitalZhongshan hospitalAlbumin gebundenem paclitaxelErstlinie toxicity levelsThe chinese academy of medical